William Abramovits M.D.

Gupta, A. K., R. P. Love, W. Abramovits and K. D. Vincent (2019). “Duobrii (Halobetasol Propionate and Tazarotene) Lotion for Topical Use: A Newly Approved Combination Corticosteroid and Retinoid Topical Treatment of Plaque Psoriasis in Adults.” Skinmed 17(3): 181-183.

Full text of this article.

Abstract or excerpt unavailable.

Gupta, A. K., R. P. Love, W. Abramovits and K. D. Vincent (2019). “Dupixent(R) (Dupilumab): A Newly Approved Interleukin-4 Receptor Antagonist for the Treatment of Atopic Dermatitis in Pediatric Patients.” Skinmed 17(2): 107-109.

Full text of this article.

No abstract or preview of this article is available.

Abramovits, W., A. Wiqas, K. D. Vincent, S. G. Versteeg and A. K. Gupta (2019). “Tremfya (Guselkumab).” Skinmed 17(1): 36-38.

Full text of this article.

Tremfya™ is the first biologic in the class of anti-IL-23 antibodies to be marketed. There are two other promising options pending for approval and about to enter the market. Being first to market has afforded guselkumab uncontested prescription competitiveness when a biologic of this class is desired. Theoretical superiority of this and other anti-IL-23 biologics over anti-IL-17, anti-IL-12/23, or anti-TNF¬ biologics is being contested with head-to-head studies. Some studies have proved the superiority of anti-IL-23 antibodies in some parameters. Clinicians have the opportunity to choose the best performing and safest treatment, individualizing the needs and risks, which sometimes depend on comorbidities, like inflammatory bowel disease, for their patients with psoriasis and psoriatic arthritis. (Excerpt from text, p. 38; no abstract available.)

Abramovits, W., A. Wiqas, K. D. Vincent, S. G. Versteeg and A. K. Gupta (2018). “Cimzia (Certolizumab Pegol).” Skinmed 16(6): 400-402.

Full text of this article.

CIMZIA (certolizumab pegol) is a recombinant monovalent monoclonal antibody with a specificity for tumor necrosis factor (TNF-a). This TNF blocker is a humanized antigen-binding fragment (Fab) with an attached polyethylene glycol polymer (PEG2MAL40K). This attached polyethylene glycol enhances the bioavailability of the Fab fragment and extends its half-life. In May 2018, certolizumab pegol was approved for the treatment of moderate-to-severe plaque psoriasis. It is also indicated for the treatment of moderate-to-severe active Crohn’s disease, moderate-to-severe rheumatoid arthritis, active psoriatic arthritis, and active ankylosing spondylitis. Certolizumab pegol is manufactured by UDB, Inc. and is available in a single-dose pre-filled syringe for patient administration and a lyophilized powder (200 mg) for reconstitution for administration by a healthcare professional. (Excerpt from text, p. 400; no abstract available.)

Abramovits, W. (2019). “Conceptual issues in dermatology and medicine: Where do nonphysician practitioners rightfully belong-a dermatologist’s perspective.” Clin Dermatol 37(1): 12-15.

Full text of this article.

The invasion of the turf of medicine by nonphysician practitioners has not spared dermatology. The reasons behind this phenomenon are complex, as so many political issues are; some may be reasonable, others concerning. An undeniable consequence is that patients are being cared for by providers with significantly lower levels of medical education than that of medical doctors. The proper practice of dermatology, a visual specialty, is unquestionably dependent on experience complemented by scientific information; for this, years of postgraduate education are required. In this article, I expose, as I was invited to do with limitations, my opinions about the concept of having “midlevels,” providing medical care to patients afflicted by skin disease.